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Abstract 31 
Mitochondrial dynamics refers to the constant remodelling of mitochondrial populations 32 
by multiple cellular pathways which help maintain mitochondrial health and function. 33 
Disruptions to mitochondrial dynamics often leads to mitochondrial dysfunction, which is 34 
frequently associated with disease in rodents and humans. Consistent with this, obesity 35 
is associated with reduced mitochondrial function in white adipose tissue, partly via 36 
alterations in mitochondrial dynamics. Several proteins are known to regulate 37 
mitochondrial dynamics including the E3 ubiquitin ligase MARCH5; however, the role of 38 
these proteins in adipocytes has been poorly studied.  Here, we show that MARCH5 is 39 
regulated by PPAR during adipogenesis and is correlated with fat mass across a panel 40 
of genetically diverse mouse strains, in ob/ob mice, and in humans. Furthermore, 41 
manipulation of MARCH5 expression both in vitro and in vivo alters mitochondrial 42 
function, affects cellular metabolism and leads to differential regulation of several 43 
metabolic genes. Thus, our data demonstrate a link between mitochondrial dynamics 44 
and metabolism which defines MARCH5 as a critical link between these interconnected 45 
pathways.  46 
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Introduction  47 
Mitochondria are essential organelles whose primary role in mammalian cells is to 48 
generate cellular energy. However, they also have crucial roles in maintaining 49 
processes such as calcium signalling, cell growth and division, apoptosis and cell death 50 
(23).  Historically, the bulk of studies investigating mitochondrial disease have been 51 
performed in tissues of high energy demand, including striated muscles and the brain.  52 
However, more recent studies have also demonstrated that manipulating mitochondrial 53 
health and activity in adipose tissue can have profound effects on adipose tissue 54 
expansion and differentiation, a process largely regulated by the nuclear receptor 55 
peroxisome proliferator-activated receptor gamma (PPAR) (35). PPAR is the master 56 
regulator of adipogenesis and consequently modulates several gene sets necessary for 57 
adipocyte function, including those involved in mitochondrial homeostasis (40, 41). 58 
Indeed, the thiazolidinediones or TZDs such as pioglitazone, which are indicated for 59 
type 2 diabetes in humans, are ligands for PPAR and have been shown to have 60 
beneficial effects on adipose tissue expansion and mitochondrial activity in individuals 61 
with obesity and type 2 diabetes (T2D) (6, 22). 62 
 63 
Mitochondrial integrity is fundamental to maintaining healthy cellular functions.  Indeed, 64 
when mitochondria become dysfunctional or damaged, overall cellular health 65 
deteriorates which can induce apoptosis and cell death (18, 27, 30, 46).  Mitochondria 66 
continually divide and fuse through well described mechanisms of fission 67 
(fragmentation) and fusion (elongation) to regulate mitochondrial health, including the 68 
removal of dysfunctional and unhealthy mitochondria through mitophagy (11, 13, 19).  69 
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These processes, collectively known as mitochondrial dynamics, are part of a highly 70 
regulated and co-ordinated program which sees mitochondria enter a constant state of 71 
flux through processes such as biogenesis, fusion, fission and mitophagy (1, 13).  72 
Several key proteins have been identified to regulate mitochondrial fission and fusion 73 
including dynamin-1-like protein (Drp1), dynamin-like 120kDa protein (optic atrophy 1- 74 
OPA1), and mitofusins 1 and 2 (Mfn1/2) (8, 44).  Mitochondrial dynamics is also 75 
important in maintaining the health of white adipose tissue (WAT), as studies have 76 
shown that inhibition of autophagy or mitophagy results in a severe reduction in WAT 77 
mass reminiscent of lipodystrophy (10, 32, 47).  Improving mitochondrial health by 78 
increasing mitochondrial function has the potential to restore or improve the function of 79 
WAT. This was elegantly highlighted by Scherer and colleagues, who demonstrated 80 
substantial improvement in metabolic health in a mouse model of obesity that 81 
specifically overexpressed the protein MitoNEET in adipose tissue (12). 82 
 83 
Another protein more recently implicated in mitochondrial dynamics is Membrane 84 
Associated Ring-CH-Type Finger 5 (MARCH5) (3, 20, 37).  The MARCH family of 85 
proteins are RING type transmembrane E3 ubiquitin ligases that regulate a range of 86 
cellular processes by ubiquinating target proteins and facilitating their degradation (28).  87 
MARCH5 is the only member of the MARCH family localised to the mitochondria where 88 
it is bound to the outer mitochondrial membrane (OMM) with the active E3 ligase 89 
domain protruding into the cytosol.  MARCH5 has been implicated in the regulation of a 90 
variety of cellular processes including apoptosis, viral signalling, endoplasmic reticulum-91 
mitochondria binding and calcium dynamics. However, the most well documented role 92 
for MARCH5 is its ability to ubiquitinate and regulate several mitochondrial dynamics 93 
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proteins including Drp1, Mfn1/2, mitochondrial fission 1 protein (Fis1) and mitochondrial 94 
dynamics proteins 49 & 51kDa (Mid49/51) (3, 33, 42, 43) .  Furthermore, recent studies 95 
have demonstrated that MARCH5 is a regulator of hypoxia induced apoptosis and 96 
mitophagy via the ubiquitination of the mitochondrial receptor FUN14 domain-containing 97 
protein 1 (FUNDC1), demonstrating a further link between MARCH5 and mitophagy 98 
pathways (2).  To date, most studies on MARCH5 have been performed in neuronal 99 
cells and tissues, and there has been no investigations into the role of MARCH5 in 100 
metabolic tissues including adipose tissue.  Thus, the current study aimed to investigate 101 
the role of MARCH5 in adipose tissue. We provide in vitro and in vivo evidence that 102 
MARCH5 expression is enriched in adipose tissue and is regulated by PPAR, and that 103 
modulation of MARCH5 in adipocytes regulates energy metabolism.    104 
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Results 105 
MARCH5 expression is reduced in obesity and correlates with PPAR expression.  106 
Initially, we aimed to determine if MARCH5 expression was correlated with measures of 107 
adiposity and obesity in mice and humans. Thus, we analysed data from a collection of 108 
genetically diverse mouse strains known as the hybrid mouse diversity panel (HMDP), 109 
that has demonstrated utility in identifying genetic drivers of complex traits (25, 26, 31). 110 
We explored data from the HMDP microarray expression profiles to analyse March5 111 
transcript expression in white adipose tissue (WAT) across 101 strains of HMDP mice 112 
fed a HFD (25).  The heat map in Figure 1A, demonstrates that March5 mRNA 113 
expression is strongly negatively correlated with several indices of adiposity including fat 114 
mass, percent body fat and the weight of multiple fat pads including retroperitoneal 115 
(RFP), gonadal (GFP), subcutaneous (FFP) and mesenteric (MFP) (Fig 1A & 1B).  116 
These data also confirm that the majority of adiposity measurements in the HMDP 117 
strains positively correlate with each other, and with indices of metabolic dysregulation 118 
(plasma glucose and insulin levels), accurately replicating known phenotypes 119 
associated with metabolic syndrome.  Consistent with MARCH5 being a mitochondrial 120 
protein and reduced in the setting of increased adiposity, we also reveal that several 121 
other mitochondrial genes (Dnm1l, Mff, Opa1, Rhot1 and Mfn1) were negatively 122 
correlated with fat mass in the HMDP (Table 1).  Additionally, to validate this interaction 123 
in an experimental model of obesity, we analysed March5 expression in WAT of male 124 
C57Bl/6J and ob/ob mice, which further demonstrated that March5 expression was 125 
reduced in the setting of increased adiposity (Fig 1C) 126 
 127 
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Given this correlation between March5 and fat mass in rodent models, we next sought 128 
to determine whether March5 expression was also decreased in association with 129 
increasing adiposity in humans.  Subsequently, we analysed the expression of March5 130 
in abdominal subcutaneous adipose tissue biopsies from participants in the METSIM 131 
Study (770 participants across a range of obesity indices (4). These data demonstrate a 132 
significant negative correlation of March5 with fat mass (r= -0.202, p=9.75e-9), 133 
consistent with data from the HMDP strains and confirming that March5 expression is 134 
negatively correlated with adiposity in both mice and humans (Fig 1B, 1D).  Finally, in 135 
order to validate correlation data from the human METSIM study, we performed 136 
Western blot analysis on subcutaneous WAT biopsies collected from a small cohort of 137 
age-matched  male participants across lean and obese groups (52.8±10.8 vs 54.2±8.4 138 
years old, respectively). These data demonstrate that those in the obese group 139 
(BMI=33.0±4.2kg/m2) with subsequently impaired fasting blood glucose levels (iFBG = 140 
9.9±3.3 mmol/L), had a lower abundance of PPAR and MARCH5 protein in their WAT 141 
compared with lean individuals (lean = 25.3±3.3kg/m2), who were normal glucose 142 
tolerant (NGT = 5.0±0.4 mmol/L), confirming that MARCH5 is reduced in the setting of 143 
obesity and metabolic dysregulation, further suggesting that pathways important to 144 
adipocyte expansion are also downregulated in obesity (Fig 1E-G).  Collectively, these 145 
data demonstrate that MARCH5 expression has a strong negative relationship with fat 146 
mass in both rodents and humans, and that pathways associated with adipogenesis 147 
(PPAR) and mitochondrial function are co-ordinately down regulated in WAT in the 148 
setting of obesity.   149 
 150 
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MARCH5 expression correlates with PPAR and is a likely PPAR target gene.  To 151 
investigate whether MARCH5 and PPAR expression are co-ordinately regulated as 152 
suggested by data in Figure 1, we again probed microarray datasets from WAT in the 153 
HMDP mouse strains.  Figure 2A plots transcripts in WAT that positively correlated 154 
(r>0.4) with Pparg gene expression across all strains of the HMDP mice. Several well 155 
described PPAR target genes were strongly positively correlated with Pparg 156 
expression in this analysis (red dots) including Hibadh, Pex13, Osbpl11 and β-Klotho.  157 
Interestingly, the most strongly correlated transcript with Pparg was March5 (blue circle 158 
and arrow, Fig 2A).  These data demonstrate that correlation analysis is a useful 159 
approach to identify PPAR regulated genes, which implicated March5 as a PPAR 160 
target gene.  To provide further evidence for this, we performed pathway enrichment 161 
analysis of all transcripts that positively correlated with Pparg at a mid-weight 162 
bicorrelation (bicor) cut-off of r>0.5, equating to 173 individual genes (Table 2).  This 163 
analysis displayed strong enrichment for pathways including mitochondria, peroxisome 164 
and lipid/fatty acid metabolism (Fig 2B), consistent with pathways classically regulated 165 
by PPAR and supporting the notion that this gene set is indeed reflective of PPAR 166 
transcriptional activity. 167 
 168 
Considering that March5 was strongly correlated with PPAR expression in WAT, we 169 
performed further experiments to investigate its tissue distribution in mice.  MARCH5 170 
protein levels were robustly detected in both brown adipose tissue (BAT) and gonadal 171 
WAT in C57BL/6J mice as shown by Western blot analysis (Fig 2C).  Furthermore, 172 
qPCR analysis of several tissues from male WT mice demonstrated that March5 173 
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expression was enriched in WAT and BAT compared to other tissues such as heart, 174 
skeletal muscle and liver (Fig 2D), consistent with March5 being a transcriptional target 175 
of PPAR. To directly test whether March5 was a transcriptional target of PPAR and 176 
regulated by the adipogenic transcriptional program, we analysed existing PPAR, 177 
RXRα and C/EBPα ChIP-Seq datasets from differentiating adipocytes and investigated 178 
whether these pro-adipogenic transcription factors (TFs) were enriched on the March5 179 
locus (14, 16).  These data confirm that all three TFs occupied the March5 promoter in 180 
close proximity to the transcriptional start site (TSS) (Figure 2E), confirming that PPAR, 181 
RXRα and C/EBPα co-operatively regulate the expression of March5, similar to that 182 
shown for other adipogenic genes (16).  These findings are strengthened by data shown 183 
in figures 2F & 2G, which present findings from primary adipocytes isolated from WT 184 
and adipocyte specific PPAR-KO mice (PPAR floxed [WT] and PPAR floxed + aP2 185 
Cre [PPAR-KO], respectively).  These data confirm that WT adipocytes differentiated 186 
proficiently, however consistent with the known role of PPAR in adipogenesis, PPAR-187 
KO adipocytes had a severely impeded ability to differentiate.  In WT adipocytes, 188 
March5 expression was upregulated upon differentiation, however this effect was 189 
completely blunted in PPAR-KO differentiated cells, and was also lower in 190 
undifferentiated PPAR-KO cells.  Thus, the data presented above provide compelling 191 
evidence that March5 is transcriptionally regulated by PPAR and the adipogenic 192 
program, and is subsequently highly enriched in adipose cells and tissue in vitro and in 193 
vivo respectively. 194 
 195 
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Mitochondrial proteins including MARCH5 are upregulated during adipocyte 196 
differentiation.  Given several studies have demonstrated that MARCH5 influences 197 
proteins which regulate mitochondrial dynamics including Mfn2 and Drp1 (9, 16, 20), we 198 
investigated this pathway in our own experimental models.  Accordingly, we performed 199 
Western blotting in immortalised MEFs isolated from WT and MARCH5-KO mice and 200 
demonstrated that loss of MARCH5 in these cells promotes an increase in Mfn2 protein 201 
abundance (Fig 3A).  This is consistent with other studies which have demonstrated that 202 
Mfn2 is ubiquinated by MARCH5 and subsequently degraded, thereby promoting an 203 
environment that would induce mitochondrial fusion (20, 33). 204 
 205 
We also determined whether MARCH5 was regulated in adipocytes independently of 206 
other mitochondrial proteins, or whether it was part of a global mitochondrial change in 207 
differentiating adipocytes as eluded to above.  To investigate this, we performed 208 
immunoblotting of proteins from WT 3T3-L1 adipocytes at different stages of adipocyte 209 
differentiation (pre-diff, day 0, day 1, day 3, day 6 and day 10).  Figures 3B & 3C confirm 210 
that MARCH5, Drp1 and Mfn2 increased substantially in adipocytes from day 3 of 211 
differentiation, which coincided with an increase in PPAR2 expression (the adipocyte 212 
specific variant - upper band).  Furthermore, other mitochondrial proteins were also 213 
increased at this time point including proteins of the electron transport chain (complex II-214 
V) and Porin (Vdac1).  These findings are consistent with PPAR and adipocyte 215 
differentiation promoting an upregulation of genes related to increasing mitochondrial 216 
activity, including an increase in MARCH5.  Because we show that MARCH5 is 217 
increased in differentiating adipocytes, and that MARCH5 deletion leads to an increased 218 
11 
 
abundance of Mfn2, we wanted to determine if MARCH5 could play a key role in 219 
regulating adipocyte mitochondrial fusion, metabolism and lipid storage. 220 
 221 
Manipulating MARCH5 abundance in 3T3-L1 adipocytes regulates mitochondrial 222 
respiration and glycolysis.  In order to investigate the functional effect of MARCH5 in 223 
differentiating adipocytes, we generated stable MARCH5 knockdown (shMARCH5) and 224 
control knockdown (shLuc) 3T3-L1 adipocytes using lentiviral delivered shRNAs.  Figure 225 
4 confirms an average 50% knockdown of March5 at various stages of differentiation 226 
(Fig 4A), with nearly 80% reduction in the early stages of differentiation, the critical time 227 
point we demonstrate that MARCH5 sharply increases in WT cells.  Figure 4 also shows 228 
that depletion of MARCH5 in 3T3-L1 adipocytes had no effect on expression of genes 229 
involved in adipocyte differentiation and mitochondrial dynamics including Pparg (Fig 230 
4B), Dnm1L (Fig 4C) and Mfn2 (Fig 4D). Despite observing no change in Dnm1L and 231 
Mfn2 gene expression, we and others have demonstrated that MARCH5 is an upstream 232 
protein regulator of the outer mitochondrial fusion protein Mfn2. To determine if 233 
depletion of MARCH5 in 3T3-L1 adipocytes modulated mitochondrial fusion, we stained 234 
MARCH5 knockdown and control cells with MitoTracker Deep Red and performed 235 
confocal microscopy. Mitochondrial populations in MARCH5 knockdown adipocytes 236 
were observed to be elongated and networked  compared with fragmented mitochondria 237 
in control cells (Fig 4E), which was significant upon quantification (Fig 4F), confirming 238 
that depletion of MARCH5 in adipocytes promoted a pro-fusion phenotype. Moreover, 239 
western blotting for Mfn2 was also observed to be elevated in March5 depleted cells 240 
(Fig 4G), providing further evidence of a pro-fusion phenotype in these cells.   241 
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 242 
Because of the tight associations between mitochondrial function and energy 243 
metabolism, we investigated whether MARCH5 knock-down and control adipocytes had 244 
altered substrate storage and utilisation. Although MARCH5 depletion promoted 245 
mitochondrial fusion, Oil Red O staining for neutral lipid abundance did not show a 246 
significant difference in the MARCH5 depleted cells (Fig 4H, 4I).  Furthermore, we also 247 
demonstrated that both basal and insulin stimulated glucose uptake was approximately 248 
2-fold higher (5168±715 vs 9124±1814 cpm/mg and 10293±1127 vs 17191±612 249 
cpm/mg, p<0.05) in MARCH5 knockdown cells, suggesting that depletion of MARCH5 250 
led to an increased reliance on carbohydrate metabolism (Fig 4J).  251 
 252 
Finally, because of the observed effects on mitochondrial fusion and apparent 253 
preference for carbohydrate metabolism, we investigated metabolic parameters and 254 
mitochondrial function using the Seahorse Flux Analyser. The Seahorse apparatus 255 
provides measures of cellular oxygen consumption rate (OCR - surrogate readout of 256 
oxidative phosphorylation) and extracellular acidification rate (ECAR – surrogate 257 
readout of glycolysis). Our data demonstrated that MARCH5 knockdown in adipocytes 258 
increased basal mitochondrial respiration as indicated by an increased basal OCR, 259 
which coincided with an increase in ATP linked respiration (Fig 4L).  In addition, 260 
MARCH5 knockdown adipocytes had increased rates of glycolysis (Fig 4M) compared 261 
with control cells, further suggesting that MARCH5 depletion modulates glucose 262 
metabolism and subsequently increases mitochondrial metabolism. This is effect on 263 
glycolysis was also supported by qPCR data demonstrating that depletion of MARCH5 264 
increases the expression of the glycolytic enzyme Pyruvate dehydrogenase kinase 265 
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(Pdk4) (Fig 4K), consistent with observed increases in ECAR measured by the 266 
Seahorse. 267 
 268 
In light of the results observed for MARCH5 depletion in adipocytes, we sought to 269 
determine whether reciprocal effects would be observed following overexpression of 270 
MARCH5. This was achieved by infecting differentiated 3T3-L1 cells with adenoviruses 271 
that express MARCH5 or a control protein (GFP).  Following adenoviral transduction, 272 
robust expression of (Fig 4N) Gfp and (Fig 4O) March5 mRNA was demonstrated  at 273 
day 7 post differentiation (1±0.1 vs 0±0.0 fold change and 2±1.5 vs 72±5 fold change 274 
relative to Gfp expression, respectively, p<0.05).  Using qPCR and the Seahorse 275 
analyser we revealed that differentiated 3T3-L1 cells overexpressing MARCH5 had 276 
reduced Pdk4, basal respiration and glycolysis compared with cells overexpressing 277 
GFP, however these cells still retained the capacity to increase mitochondrial respiration 278 
following FCCP stimulated mitochondrial uncoupling (Fig 4P, 4Q & 4R).  This is in 279 
contrast to MARCH5 knockdown, which promoted an increase in basal respiration and 280 
glycolysis compared with control cells (Fig 4L & 4M). Thus, these results indicate that 281 
manipulation of MARCH5 expression may reciprocally alter metabolic function, which 282 
coincides with a change in mitochondrial fusion, providing evidence that manipulating 283 
MARCH5 alters cellular respiration. 284 
   285 
MARCH5 overexpression in vivo alters the expression of metabolic genes.   286 
To validate the ability for MARCH5 to regulate adipocyte metabolism, we performed in 287 
vivo experiments in 4-week old male C57BL/6J mice (n=6/group).  In these mice we 288 
injected MARCH5- or Control-recombinant adeno-associated viruses (rAAV6, 1e11vg) 289 
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subcutaneously into contralateral (opposing) inguinal fat pads of the same mouse 290 
(control on left side, MARCH5 on right side).  Mice were recovered and housed for 4 291 
weeks on a HFD to promote adipose tissue expansion (data not shown), before being 292 
culled and inguinal fat pads extracted for analysis.  Gene expression analysis of the 293 
subcutaneous fat pads confirmed overexpression of March5 (6.7±3.8 vs 7145±3095 fold 294 
change relative to control, p<0.05), and also demonstrated that MARCH5 295 
overexpression in adipose tissue led to increased expression of genes associated with 296 
adipose tissue expansion and mitochondrial biogenesis including Ppargc1a, Ppargc1b, 297 
and Pparg2 (Fig 5A & 5B).  In addition, MARCH5 overexpressing fat pads exhibited 298 
increased expression of mitochondrial dynamics genes including Mfn1, Mfn2 and Dnm1l 299 
(Fig 5C).  There was no change in expression of indices of apoptosis including Cytc, 300 
Fundc1 and Bcl2 (Fig 5D).  MARCH5 overexpression also induced an increase in genes 301 
involved in lipid and peroxisome metabolism including Fasn, Cd36, Pnpla2, Cpt2, Crat 302 
and Crot, and reduced expression of genes that promote lipid catabolism including 303 
Prkab1 and Prkab2 (AMPK subunits) (Fig 5E). The robust reductions in Fasn were also 304 
observed in our MARCH5 knockdown 3T3-L1 cells (Supporting Information Fig S3), 305 
consistent with Fasn being a potentially critical gene in the MARCH5 phenotype. 306 
Collectively, these data are consistent with the hypothesis that MARCH5 regulates 307 
mitochondrial dynamics and lipid metabolism in adipose tissue in vivo, similar to that 308 
observed in 3T3-L1 adipocytes.  309 
 310 
Overall, our data demonstrate that MARCH5 expression regulates mitochondrial 311 
metabolism in adipocytes both in vitro and in vivo, and this is likely due to its role in 312 
modulating mitochondrial dynamics and substrate utilisation in the mitochondria. 313 
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Discussion 314 
Maintaining an appropriate ability to manipulate mitochondrial dynamics and thus 315 
health, is critical for the maintenance of overall cellular health.  MARCH5 is an outer 316 
mitochondrial membrane protein that has been shown to regulate several processes 317 
involved in maintaining mitochondrial dynamics including fusion, fission and apoptosis 318 
(34).  Furthermore, several studies over the past 5-10 years have demonstrated an 319 
important role for mitochondrial activity to impact on adipose tissue health and function.  320 
Here, we show that MARCH5 is highly enriched in both white and brown adipose tissue, 321 
suggesting that MARCH5 is critical to adipocyte function.   322 
 323 
Given that MARCH5 is a mitochondrial associated protein, it is reasonable to assume 324 
that it might be highly expressed in tissues that are high in mitochondria.  However, our 325 
data does not support this notion, particularly with respect to the low expression 326 
observed in skeletal muscle (which is high in mitochondria), and high expression in 327 
WAT (which is low in mitochondria). Instead, our data provides strong evidence that 328 
MARCH5 is regulated by the adipogenic program, consistent with its enriched 329 
expression in adipose tissues.  Indeed, we observed that MARCH5 expression in 330 
adipocytes is likely regulated by the nuclear receptor PPAR, and that experimentally 331 
manipulating MARCH5 expression regulates mitochondrial respiration in adipocytes.  332 
This study is the first to demonstrate that MARCH5 is regulated by PPAR during 333 
adipocyte differentiation. Importantly, suppression of PPAR expression in hypertrophic 334 
adipocytes is observed in the setting of obesity, and this may explain the reduction in 335 
mitochondrial gene expression, including March5.  This notion is supported by our 336 
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findings showing that March5 expression is negatively correlated with fat mass in 337 
rodents and humans, and that March5 is directly regulated by PPAR as shown by 338 
ChIP-Seq analysis.  It is also possible that C/EBPα plays a role in regulating the 339 
expression of March5 due to its proximity at the March5 promoter along with PPAR.  340 
Adipogenic genes are known to be regulated by both C/EBPα and PPAR during 341 
adipogenesis, and both C/EBPα and PPAR are often found to co-exist at adipogenic 342 
gene promoters in ChIP-seq datasets. We demonstrate that loss of PPAR is sufficient 343 
to prevent adipogenesis and March5 expression, however we have not performed the 344 
same experiments with C/EBPα depletion, thus the precise mechanism of regulation 345 
remains to be determined in future studies. 346 
 347 
We observed that MARCH5 expression was directly linked with mitochondrial 348 
metabolism in 3T3L1 adipocytes, since MARCH5 knockdown increased glycolysis and 349 
basal mitochondrial respiration, whilst MARCH5 overexpression decreased these 350 
parameters.  Cells overexpressing MARCH5 maintained FCCP uncoupled respiration 351 
which suggests that these mitochondria were still functioning normally when stimulated 352 
with uncoupling compounds, such as FCCP.  The mechanisms by which MARCH5 353 
manipulates adipocyte metabolism are not known and require further investigation, but 354 
may involve the ability of MARCH5 to promote mitochondrial fusion. Indeed, previous 355 
reports show that MARCH5 regulates mitochondrial fusion by ubiquinating Mfn2, 356 
thereby manipulating mitochondrial morphology and altering metabolic homeostasis (3, 357 
9, 20, 24, 33).  Our studies using confocal microscopy and western blot for Mfn2 show 358 
that knock down of MARCH5 in 3T3-L1 adipocytes promotes mitochondrial fusion 359 
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compared with control cells.  This is supported by similar observations in the fusion 360 
protein Mfn2 in immortalised MARCH5 KO MEFs, likely also facilitating a pro-fusion 361 
phenotype in these cells.   362 
 363 
Previous studies have shown that mitochondrial fusion occurs as an adaptation to 364 
starvation to promote a more energy efficient mitochondrial pool, allowing energy 365 
production to be maintained in the presence of altered substrate availability (15, 36, 38, 366 
45).  As MARCH5 expression is reduced in obesity, loss of MARCH5 might be a 367 
mechanism by which the adipocyte can promote mitochondrial fusion in an attempt to 368 
alter metabolic preferences. This may suggest MARCH5 is part of a co-ordinated 369 
interplay between metabolism, mitochondrial fusion and subsequent retained capacity to 370 
generate energy. 371 
 372 
A switch in substrate preference may also promote altered metabolic outputs, where 373 
changes in lipid metabolism or β-oxidation could lead to increased basal mitochondrial 374 
respiration, whilst maintaining other metabolic parameters such as uncoupled 375 
respiration.  Consistent with this, we observed an increase in glucose uptake in cells 376 
depleted of MARCH5, which may account for the increase in glycolysis and basal 377 
mitochondrial respiration that we observe in these cells.  Interestingly, when we 378 
overexpress MARCH5 in vivo there is an increase in the expression of key regulators of 379 
lipid metabolism, which further suggests that MARCH5 may play a role in mitochondrial 380 
substrate utilisation.  Increased expression of genes involved in lipid uptake and 381 
synthesis from subcutaneous fat pads over expressing MARCH5 suggest that the 382 
alterations in lipid metabolism could be favouring the storage of excess energy.  383 
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Notably, Crat and Crot gene expression is elevated in vivo when March5 is 384 
overexpressed. This is curious given that March5 is a PPAR target gene, and that 385 
PPAR was discovered for its role in expanding peroxisomes, thus it is possible that 386 
manipulation of MARCH5 somehow impacts on peroxisome function.   Crat and Crot 387 
also play a role in the transport of very long chain fatty acids between the peroxisome, 388 
cytosol and mitochondria.  Future studies should investigate whether MARCH5 directly 389 
degrades mitochondrial transporters, leading to a change not only in mitochondrial 390 
fusion, but also substrate utilisation.  Such a pathway would provide an elegant 391 
mechanism for regulating mitochondrial fusion, substrate utilisation and energy output in 392 
response to changes in cellular energy requirements.   393 
 394 
As the purpose of this study was to investigate the role of MARCH5 in adipose tissue, 395 
we also investigated whether MARCH5 expression was playing a role in browning of 396 
WAT.  Although we observed increased expression of MARCH5 protein in brown 397 
adipose tissue compared to WAT in mice, we were unable to show any changes in 398 
browning related genes following MARCH overexpression either in vitro or in vivo (data 399 
not shown), suggesting that MARCH5 in this setting is not affecting browning of WAT.  400 
In the context of previously published data, our findings indicate that MARCH5 likely 401 
regulates mitochondrial morphology and dynamics in adipocytes by controlling 402 
mitochondrial fusion.  Preceding studies have demonstrated that MARCH5 manipulates 403 
mitochondrial morphology by regulating the abundance of Mfn2 and Drp1, although 404 
there is some conjecture as to whether deletion of MARCH5 leads to a pro-fusion or 405 
pro-fission phenotype. Our study is the first to investigate MARCH5 in adipose cells and 406 
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tissue, and our findings suggest that loss of MARCH5 in adipocytes leads to increased 407 
mitochondrial fusion.   408 
 409 
Overall these results demonstrate that MARCH5 expression is negatively associated 410 
with fat mass, is regulated by PPAR, and that changes in MARCH5 expression can 411 
alter mitochondrial and cellular metabolism.  These functions likely alter the utilisation of 412 
lipid, which subsequently impacts glucose metabolism.  More broadly speaking, these 413 
data provide further evidence that alterations to pathways important for mitochondrial 414 
function have a significant impact on adipocyte function.  However, whether these 415 
pathways can be targeted or manipulated for metabolic benefit in vivo, remains 416 
unanswered.  417 
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Materials and Methods 418 
Cell Culture 419 
3T3-L1 cells were cultured in DMEM (GIBCO #11965-084) supplemented with 10% 420 
NBCS and maintained in 5% CO2 at 37°C.  Cells were differentiated in DMEM 421 
supplemented with 10% FBS, 20nM Insulin, 50nM GW1929, 0.5mM IBMX, 1µM DEX for 422 
48 hrs and then cultured in DMEM supplemented with 10% FBS and 20nM insulin for 10 423 
days.  WT and MITOL (MARCH5) knockout mouse embryonic fibroblasts (MEF) cells 424 
(Gift from Shigeru Yanagi, Tokyo University, Japan) were cultured in DMEM 425 
supplemented with 10% FBS and maintained in 5% CO2 at 37°C.  Primary adipocytes 426 
were isolated and cultured from inguinal fat pads as previously described (5) from floxed 427 
(fl/fl) or adipose specific PPARγ-KO (fl/fl aP2-cre) mice.  Confluent pre-adipocytes were 428 
induced to differentiate in the same media as described above to induce 3T3-L1 429 
adipocytes and imaged or harvested for protein/RNA as described below. 430 
 431 
shRNA Knockdown and MARCH5 Expression Constructs 432 
3T3-L1 adipocytes depleted for MARCH5 (shMARCH5) and control (luciferase - shLuc) 433 
were generated using commercially sourced lentiviral particles (Sigma MISSION 434 
particles) expressing shRNAs designed via the Broad Institutes RNAi Consortium 435 
database (TRCN0000246413 and SHC002V, respectively).  Briefly, 50,000 436 
undifferentiated 3T3-L1 cells were plated and exposed to lentiviruses (MOI = 20) in the 437 
presence of polybrene (10µg/mL) for 24 hours, before being changed in to normal 438 
growth medium (DMEM + 10% NBCS) overnight.  The following day positive cells stably 439 
expressing shRNAs were selected in puromycin (4µg/mL) for 4 days, before returning 440 
cells to normal growth media prior to differentiation.  Adenoviruses for human MARCH5 441 
21 
 
and GFP were generated using the VIRAPOWER kit from Invitrogen according to the 442 
manufacturer’s instructions.  Human MARCH5 cDNA was cloned from HEK293A cells.  443 
Adenoviruses were titred according to expression of their 3’ V5-tag using an in house 444 
qPCR assay (Supporting Information Table S2), and then equivalent titres added to 445 
differentiated 3T3-L1 cells at day 7.  Cells were studied on day 10.   446 
 447 
HMDP, METSIM and Human Biopsy Studies 448 
Microarray data generated from white adipose tissue (WAT) of mice in the Hybrid 449 
Mouse Diversity Panel was correlated with other transcripts and strain phenotypes as 450 
previously described (25).  Correlations were analysed as a mid-weight bicorrelation 451 
and all data presented were significant at an FDR of 5%.  METSIM data was generated 452 
by microarray analysis of adipose tissue biopsies from 770 male participants as 453 
previously described (4).  Correlation analysis was performed against 23 cardio-454 
metabolic phenotypes at an FDR of 1%.  For human samples used in western blotting 455 
analysis, subcutaneous adipose tissue biopsies were obtained using standard aseptic 456 
technique and local anaesthesia (lignocaine). A 0.5-1 cm skin incision was made ~5cm 457 
lateral to the navel/umbilicus, and a Bergstrom biopsy needle passed through to obtain 458 
approximately 1-2cm3 of subcutaneous adipose tissue under suction. All biopsies were 459 
rinsed of blood in ice-cold sterile saline, the connective tissue removed and cleaned 460 
adipose tissue was snap frozen in liquid nitrogen for subsequent storage at -80℃ until 461 
further analysis. Samples were grouped according to lean/obese and metabolic status, 462 
and blotted for indicated proteins. Pathway analysis was performed using The Database 463 
for Annotation, Visualization and Integrated Discovery (DAVID v6.8) hosted by the 464 
National Institute of Allergy and Infectious Diseases (NIAID), NIH, USA. Briefly, gene 465 
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sets were entered as a gene list in DAVID. Background adjustment was enabled against 466 
the mus musculus reference gene set and functional annotation clustering was 467 
performed with the classification stringency set at medium and p-value data presented 468 
as Benjamini-Hochberg corrected. 469 
 470 
Metabolic Flux Assays 471 
All metabolic flux analyses were performed using the Seahorse XFe96 Extracellular 472 
Flux Analyser (Agilent, Santa Clara, USA).  3T3-L1 cells were plated in a 96 well 473 
Seahorse V3-PS plate post differentiation for analyses at 1.5 x 104 cells per well.  Cells 474 
were incubated overnight at 37°C and 5% CO2 and prior to the assay the cells were 475 
washed with either OCR assay media (Seahorse XF base medium supplemented with 476 
25mM glucose, 1mM glutamine and 1mM sodium pyruvate) or ECAR assay media 477 
(Seahorse XF base medium supplemented with 1mM glutamine).  Cells were then 478 
equilibrated in 175µl/well of respective assay media and incubated at 37°C with no CO2 479 
for 30-60 minutes.  The assay protocol consisted of repeat cycles of 3 minute mix, 2 480 
minute wait and 3 minute measurement, with OCR and ECAR measured 481 
simultaneously.  Basal energetics were established after four of these initial cycles 482 
followed by either mitochondrial stress test or glycolysis stress test.  The mitochondrial 483 
stress test consists of sequential injections of the following compounds and 3 484 
subsequent repeat measurements of OCR after each:  The ATP synthase inhibitor 485 
oligomycin (1µM), the proton ionophore carbonyl cyanide-4-(trifluoromethoxy) 486 
phenylhydrazone (FCCP, 1µM), and the mitochondrial complex III and complex I 487 
inhibitors antimycin A/rotenone (1µM).  The glycolysis stress test measures ECAR and 488 
consists of sequential injections of the following compounds after four basal 489 
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measurements:  Glucose (10mM), oligomycin (1µM), and 2-deoxy-glucose (2DG, 490 
50mM), from which glycolysis and glycolytic capacity can be determined, as ECAR is a 491 
proxy measure of glycolysis.  Glycolytic capacity is the sum of the glycolytic rate and 492 
reserve glycolytic capacity.  All analysis were performed with 8-23 replicates for each 493 
independent experiment.  At the completion of each assay cells were lysed and protein 494 
concentration determined using the Bradford method (Bio-Rad, Sydney, Australia) 495 
according to the manufacturer’s instructions. 496 
 497 
Glucose Uptake Assay 498 
shLuc and shMARCH5 3T3-L1 cells were grown in 12 well plates to day 7 post 499 
differentiation and glucose uptake performed as previously described (7). 500 
 501 
Oil Red-O 502 
shLuc and shMARCH5 3T3-L1 cells were grown in 12 well plates to day 10 post 503 
differentiation to allow for lipid loading.  Cells were stained with Oil Red O as previously 504 
described (39) and imaged using an inverted Olympus IX71. 505 
 506 
SDS-PAGE and Immunoblot 507 
Cells were harvested and lysed in radio-immunoprecipitation assay (RIPA) buffer 508 
supplemented with protease and phosphatase inhibitors.  Matched protein quantities 509 
were separated by SDS-PAGE and transferred to PVDF membranes.  Membranes were 510 
blocked in 3% skim milk for 2 hours and then incubated with the appropriate primary 511 
antibody overnight at 4°C.   After incubation the membranes were probed with their 512 
respective HRP-conjugate secondary antibodies (anti mouse/rabbit) in 3% skim milk for 513 
24 
 
2 hours at room temperature, then visualised with chemiluminescence (Pierce).  The 514 
following primary antibodies were used:  PPAR (1:2000, Cell Signalling), Mfn2 (1:2000, 515 
Cell Signalling), Drp1 (1:2000, Cell Signalling), OXPHOS (1:2000, Mitosciences), Porin 516 
(1:2000, Mitosciences), SETDB1 (1:2000, ABCAM), Pan 14-3-3 (1:5000, Santa Cruz), 517 
MARCH5/MITOL (1:5000, gift from S.  Yanagi). The Image Lab Program was used to 518 
perform densitometry analyses, where all quantification results were normalised to their 519 
respective loading control (14-3-3).  Approximated molecular weights of proteins were 520 
determined from a co-resolved molecular weight standard (BioRad, #1610374). 521 
 522 
qPCR and ChIP-Seq Analysis 523 
RNA was isolated from cells and tissues using RNAzol reagent and isopropanol 524 
precipitation.  1µg of cDNA was generated from RNA using MMLV reverse transcriptase 525 
(Invitrogen) according to the manufacturer’s instructions.  qPCR was performed on 20ng 526 
cDNA using the SYBR-green method on an ABI 7500, using primer sets as outlined in 527 
Table 3. Quantification of a given gene using qPCR, was expressed by one of two ways. 528 
1. Relative mRNA level compared with control was calculated after normalisation to a 529 
housekeeping gene cyclophilin A (Ppia) or ribosomal protein-large-p0 (Rplp0) using the 530 
delta-CT method or 2. Gene expression was quantified as “normalized RNA quantity” by 531 
interpolating adjusted CT values from a log10 dilution curve previously generated for a 532 
given gene and primer set.  Primers were designed to span exon-exon junctions and 533 
were tested for specificity using BLAST (Basic Local Alignment Search Tool; National 534 
Centre for Biotechnology Information). Amplification of a single amplicon was estimated 535 
from melt curve analysis, ensuring only a single peak with an expected temperature 536 
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dissociation profile was observed.  Analysis of PPAR (GSM340799), RXRα 537 
(GSM340805), and C/EBPα (GSM678392) occupancy in proximity to March5 gene was 538 
completed using Integrated Genome Browser using publicly available ChIP-seq 539 
datasets deposited through NCBI of 3T3-L1 adipocytes after 6-days of differentiation 540 
(21, 29). 541 
 542 
Confocal 543 
Cells were grown on glass coverslips then stained with 150nM MitoTracker Deep Red 544 
(Cell Signalling) for 30 minutes.  After 3 washes in 1 X PBS, cells were fixed in 4% 545 
paraformaldehyde in PBS for 30min and then washed a further 3 times in 1 X PBS.  546 
Cells were visualised on a Confocal Nikon A1r.  Quantification of mitochondrial 547 
networking was performed using the Mitochondrial Network Analysis (MiNA) macro 548 
plugin tool for Fiji ImageJ.  Mitochondrial network size was calculated by quantifying the 549 
average number of mitochondrial branches in three different sections of individual cells 550 
(three cells per group). 551 
 552 
Animal experiments 553 
All animal experiments were approved by the Alfred Medical Research and Education 554 
Precinct (AMREP) Animal Ethics committee (E/1618/2016/B).  MARCH5 and control 555 
AAV6 vectors were generated by the Baker Institute AAV core as previously described 556 
(17).  Four week old male C57Bl/6J mice were sourced from the AMREP Animal Centre 557 
and randomly selected for injection under isoflurane with 50µl AAV solution at 1x1011 558 
vector genomes (vg) in PBS into contralateral inguinal regions (MARCH5 or control 559 
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vector on one of either sides).  These mice were then fed a high-fat diet (43% energy 560 
from fat, #SF04-001) for 4 weeks with access to food and water ad libitum.  Tissues 561 
from ob/ob mice were collected and analysed as previously described (5).  All mice 562 
were housed at 22°C on a 12hr light/dark cycle.   563 
 564 
Statistical Analysis 565 
All animal and laboratory data were expressed as mean ± standard error of the mean 566 
(SEM).  Human characteristic data from western blotting study is presented as mean ± 567 
standard deviation. All statistical analyses was performed using PRISM7 software.  568 
Groups in cell culture experiments were compared by paired students t-test. Animal 569 
studies were analysed by two-way ANOVA.  Human characteristics data were analysed 570 
by two-tailed heteroscedastic t-test. A p-value of p<0.05 was considered statistically 571 
significant. Details for mid-weight bicorrelation analysis for HMDP and METSIM 572 
datasets can be found in their respective publications, and here: 573 
https://labs.genetics.ucla.edu/lusis/links. 574 
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Table 1.  Correlation (mid-weight bicor) analysis of other mitochondrial transcripts (grey 761 
boxes) negatively correlated with fat mass in HMDP (mouse) and METSIM (human) 762 
databases. White boxes confirm a similar negative correlation with PPAR-gamma 763 
expression whilst an expected highly positive correlation was observed with leptin 764 
expression (dark grey boxes). 765 
 766 
MOUSE HUMAN
Gene r‐value p‐value Gene r‐value p‐value
Dnm1L ‐0.323 1.42E‐03 DNM1L no human probe
Mff ‐0.49 1.01E‐05 MFF ‐0.204 4.01E‐03
Opa1 ‐0.269 8.50E‐03 OPA1 ‐0.217 2.13E‐03
Rhot1 ‐0.353 4.52E‐04 RHOT1 ‐0.428 3.07E‐10
Mfn1 ‐0.501 2.36E‐07 MFN1 ‐0.203 4.05E‐03
Pparg ‐0.309 2.32E‐03 PPARG ‐0.453 2.04E‐11
Lep 0.708 1.07E‐15 LEP 0.383 2.51E‐08
 767 
 768 
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Table 2.  All transcripts that correlated with PPAR at a bicor of r>0.5 that were 770 
analysed for pathway enrichment in Figure 2B (duplicates appear as a results of 771 
multiple probes for given transcripts) 772 
 773 
Gene Symbol Gene Name R value 
March5 membrane-associated ring finger (C3HC4) 5 +0.742 
Pex13 peroxisomal biogenesis factor 13 +0.693 
Osbpl11 oxysterol binding protein-like 11 +0.684 
Ophn1 oligophrenin 1 +0.679 
Cdadc1 cytidine and dCMP deaminase domain containing 1 +0.672 
Klb klotho beta +0.672 
Osbpl11 oxysterol binding protein-like 11 +0.67 
Adhfe1 alcohol dehydrogenase, iron containing, 1 +0.664 
Mrps31 mitochondrial ribosomal protein S31 +0.647 
Sh2b2 SH2B adaptor protein 2 +0.646 
BC054059 cDNA sequence BC054059 +0.646 
Hibadh 3-hydroxyisobutyrate dehydrogenase +0.643 
4932441K18Rik RIKEN cDNA 4932441K18 gene +0.642 
Adhfe1 alcohol dehydrogenase, iron containing, 1 +0.642 
Slc1a3 solute carrier family 1 (glial high affinity glutamate transporter), 
member 3 
+0.636 
Slc1a3 solute carrier family 1 (glial high affinity glutamate transporter), 
member 3 
+0.63 
Kif13a kinesin family member 13A +0.629 
Ypel5 yippee-like 5 (Drosophila) +0.628 
Tbc1d20 TBC1 domain family, member 20 +0.625 
Rdh14 retinol dehydrogenase 14 (all-trans and 9-cis) +0.625 
Ptprm protein tyrosine phosphatase, receptor type, M +0.622 
Lipe lipase, hormone sensitive +0.619 
Trit1 tRNA isopentenyltransferase 1 +0.614 
Pex3 peroxisomal biogenesis factor 3 +0.612 
Acsl1 acyl-CoA synthetase long-chain family member 1 +0.611 
Ankrd57 ankyrin repeat domain 57 +0.606 
Cebpg CCAAT/enhancer binding protein (C/EBP), gamma +0.606 
Ormdl3 ORM1-like 3 (S. cerevisiae) +0.604 
Abhd5 abhydrolase domain containing 5 +0.604 
B3galt2 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 
2 
+0.603 
Ppp2r1b protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 
65), beta isoform 
+0.602 
Slc25a46 solute carrier family 25, member 46 +0.602 
Slc1a3 solute carrier family 1 (glial high affinity glutamate transporter), 
member 3 
+0.601 
Acsl1 acyl-CoA synthetase long-chain family member 1 +0.6 
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Hibadh 3-hydroxyisobutyrate dehydrogenase +0.6 
Acacb acetyl-Coenzyme A carboxylase beta +0.6 
Dpm1 dolichol-phosphate (beta-D) mannosyltransferase 1 +0.598 
Dtnbp1 dystrobrevin binding protein 1 +0.598 
Cdadc1 cytidine and dCMP deaminase domain containing 1 +0.597 
Pnpla2 patatin-like phospholipase domain containing 2 +0.597 
Gphn gephyrin +0.594 
Ppm1b protein phosphatase 1B, magnesium dependent, beta isoform +0.592 
B3galt2 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 
2 
+0.591 
Gpam glycerol-3-phosphate acyltransferase, mitochondrial +0.591 
Nedd4 neural precursor cell expressed, developmentally down-regulated 
4 
+0.59 
Gpam glycerol-3-phosphate acyltransferase, mitochondrial +0.589 
Tbc1d20 TBC1 domain family, member 20 +0.589 
Bag4 BCL2-associated athanogene 4 +0.589 
Bag4 BCL2-associated athanogene 4 +0.588 
Ces3 carboxylesterase 3 +0.588 
Bnip3l BCL2/adenovirus E1B interacting protein 3-like +0.587 
Nr1h3 nuclear receptor subfamily 1, group H, member 3 +0.586 
Cfd complement factor D (adipsin) +0.586 
1110002N22Rik RIKEN cDNA 1110002N22 gene +0.584 
Sfxn1 sideroflexin 1 +0.583 
Acsl1 acyl-CoA synthetase long-chain family member 1 +0.583 
Ifrd1 interferon-related developmental regulator 1 +0.583 
Parp6 poly (ADP-ribose) polymerase family, member 6 +0.581 
Eltd1 EGF, latrophilin seven transmembrane domain containing 1 +0.579 
Gys1 glycogen synthase 1, muscle +0.577 
Echs1 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial +0.576 
5730469M10Rik RIKEN cDNA 5730469M10 gene +0.576 
Baz1b bromodomain adjacent to zinc finger domain, 1B +0.574 
Lamb1-1 laminin B1 subunit 1 +0.573 
Fbxw2 F-box and WD-40 domain protein 2 +0.573 
Cat catalase +0.572 
Crat carnitine acetyltransferase +0.571 
1300001I01Rik RIKEN cDNA 1300001I01 gene +0.57 
Etv3 ets variant gene 3 +0.568 
Hspa9 heat shock protein 9 +0.568 
Atl2 atlastin GTPase 2 +0.567 
Tshr thyroid stimulating hormone receptor +0.566 
Acvr1c activin A receptor, type IC +0.566 
Csad cysteine sulfinic acid decarboxylase +0.565 
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Dnase2a deoxyribonuclease II alpha +0.564 
Aldh6a1 aldehyde dehydrogenase family 6, subfamily A1 +0.564 
Gphn gephyrin +0.563 
Nup54 nucleoporin 54 +0.561 
Dgat1 diacylglycerol O-acyltransferase 1 +0.56 
Acot4 acyl-CoA thioesterase 4 +0.559 
Orc3l origin recognition complex, subunit 3-like (S. cerevisiae) +0.559 
Sec24b Sec24 related gene family, member B (S. cerevisiae) +0.558 
Fabp4 fatty acid binding protein 4, adipocyte +0.555 
Zkscan3 zinc finger with KRAB and SCAN domains 3 +0.555 
Sox6 SRY-box containing gene 6 +0.555 
Acsm3 acyl-CoA synthetase medium-chain family member 3 +0.553 
Ncoa4 nuclear receptor coactivator 4 +0.553 
Pus10 pseudouridylate synthase 10 +0.553 
Gpcpd1 glycerophosphocholine phosphodiesterase GDE1 homolog (S. 
cerevisiae) 
+0.553 
Dbt dihydrolipoamide branched chain transacylase E2 +0.552 
Cul2 cullin 2 +0.55 
N4bp2l1 NEDD4 binding protein 2-like 1 +0.55 
Fbxw2 F-box and WD-40 domain protein 2 +0.548 
Srfbp1 serum response factor binding protein 1 +0.548 
Ephx2 epoxide hydrolase 2, cytoplasmic +0.548 
Etfa electron transferring flavoprotein, alpha polypeptide +0.547 
Hibch 3-hydroxyisobutyryl-Coenzyme A hydrolase +0.547 
Sgpl1 sphingosine phosphate lyase 1 +0.546 
Pgrmc2 progesterone receptor membrane component 2 +0.543 
St7l suppression of tumorigenicity 7-like +0.543 
Ccnl2 cyclin L2 +0.542 
Slc9a3r2 solute carrier family 9 (sodium/hydrogen exchanger), member 3 
regulator 2 
+0.542 
Pcmtd1 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain 
containing 1 
+0.542 
Ngly1 N-glycanase 1 +0.541 
Phyh phytanoyl-CoA hydroxylase +0.541 
Psmc1 protease (prosome, macropain) 26S subunit, ATPase 1 +0.541 
Tmed5 transmembrane emp24 protein transport domain containing 5 +0.541 
Sdha succinate dehydrogenase complex, subunit A, flavoprotein (Fp) +0.54 
Cox4nb COX4 neighbor +0.54 
Abhd15 abhydrolase domain containing 15 +0.54 
Vegfa vascular endothelial growth factor A +0.54 
Unknown Unannotated gene +0.54 
Ranbp9 RAN binding protein 9 +0.54 
AU018778 expressed sequence AU018778 +0.539 
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Unknown Unannotated gene +0.538 
Pitpnb phosphatidylinositol transfer protein, beta +0.538 
Pum1 pumilio 1 (Drosophila) +0.538 
Sfxn1 sideroflexin 1 +0.537 
Abhd5 abhydrolase domain containing 5 +0.537 
Mccc2 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) +0.537 
Ncoa4 nuclear receptor coactivator 4 +0.536 
Hmgcl 3-hydroxy-3-methylglutaryl-Coenzyme A lyase +0.536 
Lpl lipoprotein lipase +0.535 
Eif2b1 eukaryotic translation initiation factor 2B, subunit 1 (alpha) +0.535 
Cdadc1 cytidine and dCMP deaminase domain containing 1 +0.534 
Cirh1a cirrhosis, autosomal recessive 1A (human) +0.533 
Irs1 insulin receptor substrate 1 +0.533 
Eif3j eukaryotic translation initiation factor 3, subunit J +0.533 
Sh2b2 SH2B adaptor protein 2 +0.532 
Dpp8 dipeptidylpeptidase 8 +0.531 
Ophn1 oligophrenin 1 +0.53 
Mkks McKusick-Kaufman syndrome protein +0.53 
Eltd1 EGF, latrophilin seven transmembrane domain containing 1 +0.529 
Mgst1 microsomal glutathione S-transferase 1 +0.529 
Isca1 iron-sulfur cluster assembly 1 homolog (S. cerevisiae) +0.529 
Pnpla8 patatin-like phospholipase domain containing 8 +0.529 
C80913 expressed sequence C80913 +0.527 
Ube4b ubiquitination factor E4B, UFD2 homolog (S. cerevisiae) +0.527 
Sec24b Sec24 related gene family, member B (S. cerevisiae) +0.526 
Kif1b kinesin family member 1B +0.526 
Pcmtd1 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain 
containing 1 
+0.526 
Sgpl1 sphingosine phosphate lyase 1 +0.525 
Timp3 tissue inhibitor of metalloproteinase 3 +0.525 
Pecam1 platelet/endothelial cell adhesion molecule 1 +0.525 
Pccb propionyl Coenzyme A carboxylase, beta polypeptide +0.524 
Rad21 RAD21 homolog (S. pombe) +0.524 
Pex14 peroxisomal biogenesis factor 14 +0.523 
Atl2 atlastin GTPase 2 +0.523 
Bnip3 BCL2/adenovirus E1B interacting protein 3 +0.522 
Gosr1 golgi SNAP receptor complex member 1 +0.522 
Chpt1 choline phosphotransferase 1 +0.521 
Usp47 ubiquitin specific peptidase 47 +0.521 
1500003O03Rik RIKEN cDNA 1500003O03 gene +0.52 
Atp1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide +0.52 
Mapk6 mitogen-activated protein kinase 6 +0.52 
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Ppm1a protein phosphatase 1A, magnesium dependent, alpha isoform +0.519 
Aldh2 aldehyde dehydrogenase 2, mitochondrial +0.519 
Sfrs1 splicing factor, arginine/serine-rich 1 (ASF/SF2) +0.519 
Ywhab tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, beta polypeptide 
+0.519 
Pex3 peroxisomal biogenesis factor 3 +0.518 
Tomm70a translocase of outer mitochondrial membrane 70 homolog A 
(yeast) 
+0.518 
Sdpr serum deprivation response +0.516 
Slc27a1 solute carrier family 27 (fatty acid transporter), member 1 +0.516 
Acox1 acyl-Coenzyme A oxidase 1, palmitoyl +0.516 
Zkscan3 zinc finger with KRAB and SCAN domains 3 +0.515 
Baz1b bromodomain adjacent to zinc finger domain, 1B +0.514 
Ppargc1b peroxisome proliferative activated receptor, gamma, coactivator 1 
beta 
+0.514 
Rcl1 RNA terminal phosphate cyclase-like 1 +0.514 
Gys1 glycogen synthase 1, muscle +0.514 
Etv3 ets variant gene 3 +0.514 
Phax phosphorylated adaptor for RNA export +0.513 
Psmd4 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 +0.512 
Seh1l SEH1-like (S. cerevisiae +0.512 
Timp3 tissue inhibitor of metalloproteinase 3 +0.512 
Pabpc4 poly(A) binding protein, cytoplasmic 4 +0.511 
Crbn cereblon +0.51 
Cebpz CCAAT/enhancer binding protein zeta +0.51 
Pim3 proviral integration site 3 +0.509 
Timm50 translocase of inner mitochondrial membrane 50 homolog (yeast) +0.509 
Btf3l4 basic transcription factor 3-like 4 +0.509 
Aacs acetoacetyl-CoA synthetase +0.509 
Tfdp1 transcription factor Dp 1 +0.509 
Mtch2 mitochondrial carrier homolog 2 (C. elegans) +0.508 
Bscl2 Bernardinelli-Seip congenital lipodystrophy 2 homolog (human) +0.507 
Bscl2 Bernardinelli-Seip congenital lipodystrophy 2 homolog (human) +0.506 
Bckdha branched chain ketoacid dehydrogenase E1, alpha polypeptide +0.506 
Pex5 peroxisomal biogenesis factor 5 +0.506 
Aacs acetoacetyl-CoA synthetase +0.505 
Mknk2 MAP kinase-interacting serine/threonine kinase 2 +0.505 
Ddx27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 +0.505 
Rsl1d1 ribosomal L1 domain containing 1 +0.505 
Ubqln1 ubiquilin 1 +0.504 
Entpd5 ectonucleoside triphosphate diphosphohydrolase 5 +0.504 
Sh3glb1 SH3-domain GRB2-like B1 (endophilin) +0.504 
Psmd12 proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 +0.503 
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Snrnp48 small nuclear ribonucleoprotein 48 (U11/U12) +0.503 
Cept1 choline/ethanolaminephosphotransferase 1 +0.503 
Mapk6 mitogen-activated protein kinase 6 +0.502 
Unknown Unannotated gene +0.502 
Taf1d TATA box binding protein (Tbp)-associated factor, RNA 
polymerase I, D 
+0.501 
Stag2 stromal antigen 2 +0.501 
Hspa9 heat shock protein 9 +0.501 
Eri2 exoribonuclease 2 +0.501 
S100a1 S100 calcium binding protein A1 +0.501 
Kif1b kinesin family member 1B +0.501 
Rabggtb RAB geranylgeranyl transferase, b subunit +0.501 
Pak2 p21 protein (Cdc42/Rac)-activated kinase 2 +0.5 
Grb10 growth factor receptor bound protein 10 +0.5 
Rasip1 Ras interacting protein 1 +0.5 
Mrpl50 mitochondrial ribosomal protein L50 +0.5 
Nbn nibrin +0.5 
 774 
  775 
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Table 3.  Primers for qPCR.  (m = mouse, h = human, p = plasmid/synthetic). 776 
 777 
Gene name Primer sequence 
Forward (5’-3’) 
Primer sequence 
Reverse (5’-3’) 
mMfn2 ATTGATCACGGTGCTCTTCC GTCCTGGACGTCAAAGGGTA 
mDnm1L TGCCTCAGATCGTCGTAGTG CGTGGACTAGCTGCAGAATG 
mPparg GTGCCAGTTTCGATCCGTAGA GGCCAGCATCGTGTAGATGA 
mPparg2 GTTTTATGCTGTTATGGGTG GTAATTTCTTGTGAAGTGCTCATAG 
mMarch5 TTGGACAGCCGTGACTTATG AGGGTCAGCTCGCTCCAT 
hMARCH5 CAAAAGCCTGTCCATTTGC CCAGACCTTCTTTATGACCTACAAC 
mPgc1a TGAGGACCGCTAGCAAGTTT TGAAGTGGTGTAGCGACCAA 
mPgc1b CTGAGTCAAAGTCACTGGCG GCTCTCGTCCTTCTTCCTCA 
mCebpa TGGACAAGAACAGCAACGAG GTCACTGGTCAACTCCAGCA 
mCd36 TTGTACCTATACTGTGGCTAAATGAGA CTTGTGTTTTGAACATTTCTGCTT 
mLdlr AGGCTGTGGGCTCCATAGG TGCGGTCCAGGGTCATCT 
mSlc27a1 GACAAGCTGGATCAGGCAAG GAGGCCACAGAGGCTGTTC 
mCptc1c GTGGACAAGCACCAGGCTCT TGGACCTGGGTCAGGAAGGG 
mCpt2 ACAGTGTGGGCGAGCTTCAG GGCTGCTGCCAGATACCGTAG 
mDgat2 CACTCCAGTGGGTTCCGTGT TTTGGCCTTGACCCTTCGCT 
mBcl2 AGGGTCTTCAGAGACAGCCA AGTACCTGAACCGGCATCTG 
mCytc CAGCTTCCATTGCGGACAC CGCTGACAGCATCACCTTTC 
mFundc1 ATTGTAATGGGTGGCGTGAC CATAGCCACTGTGACTGGCA 
mFasn TGCTCCCAGCTGCAGGC GCCCGGTAGCTCTGGGTGTA 
mPnpla2 GAAATTGGGTGACCATCTGC TGGGTAGGGCCTCACTGTAG 
mCrat AACTGGCTGTCCGAGTGGTG TGGCAGCAAACCGAAGCTGA 
mCrot GACTTCATGGACGCCCTGGT ACCTGACGGCCTCCACTGTA 
mGfp CAGGAGCGCACCATCTTCTT CTTGTGCCCCAGGATGTTG 
mCidea TGCTCTTCTGTATCGCCCAGT GCCGTGTTAAGGAATCTGCTG 
mPrkaca CCCACCCTTCTTCGCTGACC GTTCCGCAGCAGGTCCTTCA 
mPrkab1 CGGGCATCTCTTGTGACCCA GCACTGAGCACCATCACTCCA 
mPrkab2 TCTCCTTGTACGCCGAACAGC CCCGCTCGCTGGTAGTGTTT 
mFabp4 GGTCGACTTTCCATCCCACTT TTCGATGAAATCACCGCAGA 
mLpl TTTGTGAAATGCCATGACAAG CAGATGCTTTCTTCTCTTGTTTGT 
mLipe GCGCTGGAGGAGTGTTTTT CCGCTCTCCAGTTGAACC 
pAD-V5 CCTAACCCTCTCCTCGGTCT TCTGTCTTTTTATTGCCGTCAT 
mPpia AGCCAAATCCTTTCTCTCCAG CACCGTGTTCTTCGACATCA 
mRplp0 ACCCTGAAGTGCTCGACATC ATTGATGATGGAGTGTGGCA 
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Figure Legends 780 
Figure1: March5 expression is negatively correlated with obesity phenotypes in 781 
rodents and humans.  (A) Heat map depicts correlations between March5 mRNA 782 
expression and adiposity/metabolism traits from mouse strains of the HMDP (n=101 783 
strains).  (B) Dot plot and linear regression of white adipose tissue (WAT) March5 784 
mRNA expression with fat mass (grams - g) as determined by EchoMRI in 101 strains of 785 
the HMDP (each dot represents an individual strain).  (C) Bar graph for March5 gene 786 
expression in WAT from wild-type (WT) and ob/ob, normalised to Cyclophilin A (Ppia) 787 
gene expression.  (D) Dot plot and linear regression of WAT March5 mRNA expression 788 
with fat mass (kilograms – kg) in 770 male individuals from the METSIM study (each dot 789 
represents one individual).  (E) Western blots for MARCH5, PPAR and 14-3-3 (loading 790 
control) from subcutaneous WAT biopsies taken from lean, normal glucose tolerant 791 
(NGT) individuals versus obese, impaired fasting blood glucose (iFBG) male individuals. 792 
(F & G) Densitometric quantification of MARCH5 and PPAR protein levels normalised 793 
to 14-3-3.  All data are presented as mean±SEM, *p<0.05 from WT or lean samples. 794 
MRI – Magnetic Resonance Imaging; FFA - Free Fatty Acid; Chol - Cholesterol; TG - 795 
Triglycerides; FFP- Femoral (subcutaneous) Fat Pad; GFP - Gonadal Fat Pad; MFP - 796 
Mesenteric Fat Pad; RFP – Retroperitoneal Fat Pad; % - Tissue weight as a percentage 797 
of total body weight. 798 
 799 
Figure 2: MARCH5 is highly expressed in adipose tissue and is regulated by 800 
PPAR.     801 
43 
 
(A)  Dot plot depicting genes significantly (FDR 5%) positively correlated (bicor r>0.4) 802 
with PPAR expression in WAT of HMDP strains; red dots = previously validated PPAR 803 
target genes, blue dot = March5. (B) Pathway enrichment analysis of genes correlated 804 
(bicor r>0.5) with PPAR in WAT from strains of the HMDP (C)  Western blots for 805 
MARCH5 and 14-3-3 (loading control) in WAT and BAT from C57BL/6J mice.  (D) Bar 806 
graph of gene expression analysis for March5 mRNA in various tissues of C57BL/6J 807 
mice (n=5, mean±SEM).  (E) ChIP-seq analysis of PPAR, RXRα and C/EBPα at the 808 
March5 locus in 3T3-L1 adipocytes (F) Photomicrographs of pre-differentiated (Pre-Diff) 809 
and differentiated (day 7 – Diff) primary adipocytes isolated from WT (PPAR floxed) 810 
and PPAR-KO (PPAR floxed + aP2-cre) C57BL/6J mice and subsequent (G) bar 811 
graph of gene expression analysis for March5 normalised to Cyclophilin A (Ppia) in 812 
those cells.  Values represent means ±SEM, * p<0.05 from non-diff WT, # p<0.05 from 813 
WT non-diff. WAT = white adipose tissue, BAT = brown adipose tissue, Hrt = heart, 814 
Quad = quadriceps, Sol = soleus, Liv = liver. 815 
 816 
Figure 3: PPAR and mitochondrial protein expression, including MARCH5 are 817 
increased during adipocyte differentiation.   818 
(A) Western blot and densitometric quantification of MARCH5 and Mitofusin2 (Mfn2) 819 
from WT and MARCH5-KO MEFs, adjusted for loading control (14-3-3).  (B & C) 820 
Western blot and densitometry analyses of adipogenic and mitochondrial proteins from 821 
pre-differentiated through day 10 post-differentiated 3T3-L1 adipocytes.  All data are 822 
presented as mean±SEM, *p<0.05.  Drp1 = dynamin related protein 1, Complex V = 823 
44 
 
Complex V of the mitochondrial electron transport chain, MEF = mouse embryonic 824 
fibroblast, DMI = dexamethasone/methyl-3-isobutylxanthine(IBMX)/insulin 825 
 826 
Figure 4: MARCH5 modulation in 3T3-L1 adipocytes alters metabolic gene 827 
expression and cellular metabolism.  Control (shLuc) and MARCH5-KD (shMARCH5) 828 
3T3-L1 adipocytes were analysed for (A-D) gene expression using qPCR analysis, 829 
presented as fold-change from control. (E) Pseudo-coloured confocal image of 830 
mitochondrial morphology in control (shLuc) and MARCH5-KD adipocytes using 831 
MitoTracker Deep Red staining (X600). Right panels are enlargements of cell areas 832 
depicted by white squares in left panels. (F) Quantification of mitochondrial networks in 833 
control (shLuc) and MARCH5-KD adipocytes, measured as the mean number of 834 
mitochondrial branches, using MiNA and Fiji Image software. (G) Western blots for 835 
Mfn2, as a measure of mitochondrial fusion and MARCH5 activity, in control (shLuc) 836 
and MARCH5-KD adipocytes at day 0 and day 6 post differentiation.  (H) Oil Red-O 837 
staining for neutral lipid deposition photomicrographs of MARCH5-KD and control 838 
(shLuc) adipocytes at low (40x) and high (200x) magnification.  (I) Quantification of 839 
neutral lipid staining from Oil-Red O imaging. (J) Glucose uptake in MARCH5-KD and 840 
control (shLUC) 3T3-L1 adipocytes.  (K)  Pdk4 gene expression in MARCH5-KD and 841 
control (shLUC) 3T3-L1 adipocytes throughout differentiation (day -3 to day 6) (L) 842 
Respirometry data from MARCH5-KD and control (shLuc) adipocytes using the 843 
Seahorse Flux analyser measuring the oxygen consumption rate (OCR) including basal, 844 
FCCP uncoupled respiration (UCP), and ATP linked respiration, and (M) extra cellular 845 
acidification rate (ECAR) as a proxy measure of glycolysis and glycolytic capacity.  846 
Gene expression analysis from differentiated 3T3-L1 cells infected with adenoviruses for 847 
45 
 
(N) Gfp and (O) March5.  (P)  Pdk4 gene expression in MARCH5 overexpressing and 848 
control (GFP) 3T3-L1 adipocytes.  Seahorse analysis on control (GFP) and MARCH5 849 
overexpressing cells plotting (Q) OCR and (R) ECAR.  All values presented as 850 
mean±SEM, *p<0.05 vs control (shLuc or GFP Tg).  851 
 852 
Figure 5: MARCH5 over expression in white adipose tissue of C57BL/6J mice 853 
alters expression of metabolic and mitochondrial genes.  C57BL/6J mice at 4 854 
weeks of age received contralateral injections of control (MCS) or MARCH5 AAVs 855 
(rAAV6) subcutaneously into developing inguinal fat pads and were fed a HFD for 4 856 
weeks.  Bar graphs depicting gene expression in excised control-AAV and MARCH5-857 
AAV subcutaneous fat pads of the same animal for (A) MARCH5, (B) adipogenic genes, 858 
(C) mitochondrial fusion and fission genes, (D) apoptosis genes and (E) lipid 859 
metabolism genes.  All data presented as mean±SEM, *p<0.05 from control (MCS-860 
AAV). 861 
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Figure 5 
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